PRIVA-PRAVASTATIN TABLET

מדינה: קנדה

שפה: אנגלית

מקור: Health Canada

מרכיב פעיל:

PRAVASTATIN SODIUM

זמין מ:

PHARMAPAR INC

קוד ATC:

C10AA03

INN (שם בינלאומי):

PRAVASTATIN

כמות:

40MG

טופס פרצבטיות:

TABLET

הרכב:

PRAVASTATIN SODIUM 40MG

מסלול נתינה (של תרופות):

ORAL

יחידות באריזה:

100/500

סוג מרשם:

Prescription

איזור תרפויטי:

HMG-COA REDUCTASE INHIBITORS

leaflet_short:

Active ingredient group (AIG) number: 0122563003; AHFS:

מצב אישור:

CANCELLED POST MARKET

תאריך אישור:

2022-07-29

מאפייני מוצר

_Priva-PRAVASTATIN _
_ _
_Page 1 of 37 _
PRODUCT MONOGRAPH
PR
PRIVA-PRAVASTATIN
Pravastatin Sodium Tablets, USP
10 mg, 20 mg and 40 mg
LIPID METABOLISM REGULATOR
PHARMAPAR INC.
DATE OF PREPARATION:
100-5950, Ch. de la Côte de Liesse
September 1, 2015
Mont-Royal
Qc, H4T 1E2
Control # 186294
_Priva-PRAVASTATIN _
_ _
_Page 2 of 37 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION................................................................
3
SUMMARY PRODUCT INFORMATION
....................................................................................
3
INDICATIONS AND CLINICAL USE
..........................................................................................
3
CONTRAINDICATIONS
...............................................................................................................
5
WARNINGS AND PRECAUTIONS
..............................................................................................
5
ADVERSE REACTIONS
..............................................................................................................
10
DRUG INTERACTIONS
..............................................................................................................
13
DOSAGE AND ADMINISTRATION
..........................................................................................
15
OVERDOSAGE
............................................................................................................................
16
ACTION AND CLINICAL PHARMACOLOGY
........................................................................
16
STORAGE AND STABILITY
......................................................................................................
18
DOSAGE FORMS, COMPOSITION AND PACKAGING
......................................................... 18
PART II: SCIENTIFIC INFORMATION
.....................................................................................
19
PHARMACEUTICAL INFORMATION
......................................................................................
19
C